Vivoryon Therapeutics VVY

AMS: VVY | ISIN: NL00150002Q7 15/09/2026

1,100 EUR (-1,35%)

(-1,35%) 15/09/2026

Grafiek Vivoryon Therapeutics AG

Grafiek Vivoryon Therapeutics AG

1 dag1d -1,35%
1 week1w -2,65%
1 maand1m -3,51%
3 maanden3m 2,80%
6 maanden6m -19,71%
1 jaar1j -33,09%
5 jaar5j -94,17%

Vivoryon Therapeutics AG in het nieuws

Toon enkel gratis nieuws

18 augustus 2026 · Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 · Persbericht

6 augustus 2026 · Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update · Persbericht

22 juli 2026 · Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026 · Persbericht

11 juni 2026 · Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update · Persbericht

8 juni 2026 · Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026 · Persbericht

23 april 2026 · Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update · Persbericht

15 april 2026 · Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026 · Persbericht

9 april 2026 · Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference · Persbericht

28 maart 2026 · Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology · Persbericht

7 januari 2026 · Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences · Persbericht

Profiel Vivoryon Therapeutics AG

Gezondheidstechnologie

Website: www.probiodrug.de

Hoofdzetel: Halle Duitsland

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe